Compare · CLOV vs NTRA
CLOV vs NTRA
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.84B, about 15.3x CLOV ($2.02B).
- Over the past year, CLOV is up 30.9% and NTRA is up 30.9% - NTRA leads by 0.0 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 4 for CLOV).
- NTRA has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Natera Inc.
- Price
- $3.92+2.22%
- $214.82-0.23%
- Market cap
- $2.02B
- $30.84B
- 1M return
- +39.08%
- -2.15%
- 1Y return
- +30.94%
- +30.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 4
- 16
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CLOV
- CEO, Counterpart Health Wai Conrad sold $879,500 worth of shares (220,426 units at $3.99) as part of a pre-agreed trading plan (SEC Form 4)
- Director Edwards Carladenise Armbrister sold $229,687 worth of shares (67,160 units at $3.42), decreasing direct ownership by 19% to 285,432 units (SEC Form 4)
- Interim CFO Thornton Joseph Clay covered exercise/tax liability with 16,942 shares, decreasing direct ownership by 1% to 1,217,584 units (SEC Form 4) (withholding obligation)
- Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 144 filed by Clover Health Investments Corp.
- CEO of Clover Care Services Priest Brady Patrick sold $345,097 worth of shares (98,039 units at $3.52), decreasing direct ownership by 5% to 2,040,222 units (SEC Form 4)
- Chief Executive Officer Toy Andrew covered exercise/tax liability with 85,704 shares, decreasing direct ownership by 0.86% to 9,923,301 units (SEC Form 4) (withholding obligation)
- SEC Form 10-Q filed by Clover Health Investments Corp.
- Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Clover Health Reports First Quarter 2026 Results
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma